ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Hoffmann-La Roche and Qilu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Hoffmann-La RocheQilu Pharmaceutical
studies on the registry2,744219
open to participants now114136
phase 3 studies under way9553
reach primary completion within a year7650
programswith a study of their own in two years80+25 named only72

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseHoffmann-La RocheQilu Pharmaceutical
Phase 1

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%

Qilu Pharmaceutical: 24 of its 72 programs at phase 1

  1. apripitant and palonosetron injectable emulsionphase 1
  2. follitropin alfaphase 1
  3. Meropenem-Pralubactamphase 1
  4. QL2302phase 1
  5. QLF4113phase 1

and 19 more — sign in to see them all

33%
Phase 2

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

Qilu Pharmaceutical: 14 of its 72 programs at phase 2

  1. QLS1410phase 2
  2. QLS12010phase 2
  3. KRAS G12D Inhibitor QLC1101phase 2
  4. QLH12016phase 2
  5. QLC1401phase 2

and 9 more — sign in to see them all

19%
Phase 3

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

Qilu Pharmaceutical: 32 of its 72 programs at phase 3

  1. Iparomlimab/Tuvonralimabphase 3
  2. QLC5508phase 3
  3. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3
  4. QL2107phase 3
  5. QLC7401phase 3

and 27 more — sign in to see them all

44%
Approved, new studies

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Qilu Pharmaceutical: 2 of its 72 programs at approved, new studies

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study
  2. Tafamidis Meglumine Soft Capsulesapproved, new study
3%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
Qilu Pharmaceutical37 readouts · 13 phase 3

Qilu Pharmaceutical, Nov ’26: 2 programs whose next study reaches primary completion

  1. apripitant and palonosetron injectable emulsionphase 1 · Nov 0 · NCT07817004
  2. QLS1304phase 2 · Nov 0 · NCT06823609

Qilu Pharmaceutical, Dec ’26: 9 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905phase 3 · Dec 0 · NCT06942767
  2. pralurbactamphase 3 · Dec 0 · NCT07089186
  3. QL1207Hphase 3 · Dec 0 · NCT07489586
  4. QL2107phase 3 · Dec 0 · NCT06754644
  5. QLG1091phase 3 · Dec 0 · NCT07487103

and 4 more — sign in to see them all

Qilu Pharmaceutical, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QL1206phase 3 · Jan 0 · NCT07062978
  2. QLS1510phase 1 · Jan 30 · NCT07760077

Qilu Pharmaceutical, Feb ’27: 1 program whose next study reaches primary completion

  1. QLC1401phase 2 · Feb 0 · NCT07173556

Qilu Pharmaceutical, Mar ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. QLH2405phase 1 · Mar 0 · NCT07489599
  2. QLM3003phase 3 · Mar 0 · NCT06880276

Qilu Pharmaceutical, Apr ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-HER2 Monoclonal Antibody QL1209phase 3 · Apr 0 · NCT07861139
  2. Platinum Compoundsphase 2 · Apr 0 · NCT07453394
  3. QLS1209phase 1 · Apr 0 · NCT06872580
  4. QLS5132phase 3 · Apr 0 · NCT07453394
  5. QL0911phase 3 · Apr 30 · NCT06456528

Qilu Pharmaceutical, May ’27: 4 programs whose next study reaches primary completion, 4 in phase 3

  1. Anti-B7-H3 Antibody-drug Conjugate MHB088Cphase 3 · May 0 · NCT06954246
  2. daprodustatphase 3 · May 0 · NCT07300111
  3. QL2108phase 3 · May 0 · NCT06884891
  4. QLG2128phase 3 · May 0 · NCT06898060

Qilu Pharmaceutical, Jun ’27: 7 programs whose next study reaches primary completion, 1 in phase 3

  1. Anti-TROP2 Antibody-drug Conjugate ESG401phase 3 · Jun 0 · NCT06732323
  2. Iparomlimab/Tuvonralimabphase 3 · Jun 0 · NCT07272590
  3. QL2401phase 2 · Jun 0 · NCT07620366
  4. QLC5513phase 2 · Jun 0 · NCT07272590
  5. QLS5308phase 1 · Jun 0 · NCT07462442

and 2 more — sign in to see them all

Qilu Pharmaceutical, Jul ’27: 1 program whose next study reaches primary completion

  1. QLS5133phase 2 · Jul 0 · NCT07061639

Qilu Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion

  1. QLS2406-1 injectionphase 1 · Aug 30 · NCT07937787
·

Qilu Pharmaceutical, Oct ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. QLC7401phase 3 · Oct 7 · NCT07444086
  2. QLS2312phase 1 · Oct 9 · NCT07861581
  3. QLS7402 Injectionphase 1 · Oct 29 · NCT07950462
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Qilu Pharmaceutical

New programs 7

Reached a new phase 2

  • QLS4131phase 3 · Nov 6 · Multiple Myeloma
  • QLS5132phase 3 · Oct 20 · Carcinoma, Ovarian Epithelial

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 32 in all. A program counts in each condition its studies name most.

ConditionHoffmann-La RocheQilu Pharmaceutical
Breast Neoplasmsboth · compare here

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Qilu Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL2107phase 3
  3. romiplostimphase 3
  4. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

Multiple Myelomaboth · compare here

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Qilu Pharmaceutical in Multiple Myeloma: 4 programs

  1. QL2109phase 3
  2. QLS4131phase 3
  3. QLS32015phase 3
  4. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Multiple Myeloma in search

Prostatic Neoplasmsboth · compare here

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Qilu Pharmaceutical in Prostatic Neoplasms: 5 programs

  1. QLC5508phase 3
  2. QLG1080phase 3
  3. QLH12016phase 2
  4. QLF4113phase 1
  5. QLS2401phase 1

Their studies: Qilu Pharmaceutical’s studies of Prostatic Neoplasms in search

Colorectal Neoplasmsboth · compare here

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Qilu Pharmaceutical in Colorectal Neoplasms: 2 programs

  1. Iparomlimab/Tuvonralimabphase 3
  2. QL1203phase 3

Their studies: Qilu Pharmaceutical’s studies of Colorectal Neoplasms in search

Dermatitis, Atopicboth · compare here

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Qilu Pharmaceutical in Dermatitis, Atopic: 4 programs

  1. QLM3003phase 3
  2. QL2108phase 3
  3. tezepelumabphase 3
  4. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Dermatitis, Atopic in search

Obesityboth · compare here

Hoffmann-La Roche in Obesity: 5 programs

  1. enicepatidephase 3
  2. petrelintidephase 3
  3. emugrobartphase 3
  4. tifeglipronphase 2
  5. HM17321no phase

Their studies: Hoffmann-La Roche’s studies of Obesity in search

Qilu Pharmaceutical in Obesity: 2 programs

  1. QLS2406-1 injectionphase 1
  2. QLS7402 Injectionphase 1

Their studies: Qilu Pharmaceutical’s studies of Obesity in search

Small Cell Lung Carcinomaboth · compare here
Alzheimer Diseaseboth · compare here

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Qilu Pharmaceutical in Alzheimer Disease: 1 program

  1. QLH2405phase 1

Their studies: Qilu Pharmaceutical’s studies of Alzheimer Disease in search

Lupus Erythematosus, Systemicboth · compare here

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Qilu Pharmaceutical in Lupus Erythematosus, Systemic: 3 programs

  1. QLS4131phase 3
  2. QLS2404phase 1
  3. QLS2416phase 1

Their studies: Qilu Pharmaceutical’s studies of Lupus Erythematosus, Systemic in search

Neoplasmsboth · compare here

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Qilu Pharmaceutical in Neoplasms: 2 programs

  1. QL2107phase 3
  2. QL2109phase 3

Their studies: Qilu Pharmaceutical’s studies of Neoplasms in search

Macular Degenerationboth · compare here

Hoffmann-La Roche in Macular Degeneration: 4 programs

  1. avacincaptad pegolphase 1
  2. pegcetacoplanphase 1
  3. Ranibizumabapproved, new study
  4. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Macular Degeneration in search

Qilu Pharmaceutical in Macular Degeneration: 1 program

  1. QL1207Hphase 3

Their studies: Qilu Pharmaceutical’s studies of Macular Degeneration in search

Multiple Sclerosisboth · compare here

Hoffmann-La Roche in Multiple Sclerosis: 4 programs

  1. fenebrutinibphase 3
  2. P-CD19CD20-ALLO1 Cellsphase 1
  3. RO7845860phase 1
  4. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis in search

Qilu Pharmaceutical in Multiple Sclerosis: 1 program

  1. Dimethyl Fumarate Enteric-coated Capsulesapproved, new study

Their studies: Qilu Pharmaceutical’s studies of Multiple Sclerosis in search

Arthritis, Rheumatoidboth · compare here

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Qilu Pharmaceutical in Arthritis, Rheumatoid: 1 program

  1. QLS12010phase 2

Their studies: Qilu Pharmaceutical’s studies of Arthritis, Rheumatoid in search

Diabetes Mellitus, Type 2both · compare here

Hoffmann-La Roche in Diabetes Mellitus, Type 2: 3 programs

  1. enicepatidephase 3
  2. emugrobartphase 3
  3. tifeglipronphase 2

Their studies: Hoffmann-La Roche’s studies of Diabetes Mellitus, Type 2 in search

Qilu Pharmaceutical in Diabetes Mellitus, Type 2: 1 program

  1. QLG1091phase 3

Their studies: Qilu Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Parkinson Diseaseboth · compare here

Hoffmann-La Roche in Parkinson Disease: 3 programs

  1. prasinezumabphase 3
  2. RO7568282phase 2
  3. selnoflastphase 2

Their studies: Hoffmann-La Roche’s studies of Parkinson Disease in search

Qilu Pharmaceutical in Parkinson Disease: 1 program

  1. G(M1) Gangliosidephase 3

Their studies: Qilu Pharmaceutical’s studies of Parkinson Disease in search

Conjunctivitis, Allergicboth · compare here

Hoffmann-La Roche in Conjunctivitis, Allergic: 2 programs

  1. Cyclosporineapproved, new study
  2. lifitegrastapproved, new study

Their studies: Hoffmann-La Roche’s studies of Conjunctivitis, Allergic in search

Qilu Pharmaceutical in Conjunctivitis, Allergic: 1 program

  1. lifitegrastphase 1

Their studies: Qilu Pharmaceutical’s studies of Conjunctivitis, Allergic in search

Dry Eye Syndromesboth · compare here

Hoffmann-La Roche in Dry Eye Syndromes: 2 programs

  1. Cyclosporineapproved, new study
  2. lifitegrastapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dry Eye Syndromes in search

Qilu Pharmaceutical in Dry Eye Syndromes: 1 program

  1. lifitegrastphase 1

Their studies: Qilu Pharmaceutical’s studies of Dry Eye Syndromes in search

Neoplasm Metastasisboth · compare here

Hoffmann-La Roche in Neoplasm Metastasis: 2 programs

  1. inavolisibphase 3
  2. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Neoplasm Metastasis in search

Qilu Pharmaceutical in Neoplasm Metastasis: 1 program

  1. QL1206phase 3

Their studies: Qilu Pharmaceutical’s studies of Neoplasm Metastasis in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Hoffmann-La Roche in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. astegolimabphase 3
  2. RO7830698phase 2

Their studies: Hoffmann-La Roche’s studies of Pulmonary Disease, Chronic Obstructive in search

Qilu Pharmaceutical in Pulmonary Disease, Chronic Obstructive: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Pulmonary Disease, Chronic Obstructive in search

Adenocarcinomaboth · compare here

Hoffmann-La Roche in Adenocarcinoma: 1 program

  1. autogene cevumeranphase 2

Their studies: Hoffmann-La Roche’s studies of Adenocarcinoma in search

Asthmaboth · compare here

Hoffmann-La Roche in Asthma: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Asthma in search

Qilu Pharmaceutical in Asthma: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Asthma in search

Endometrial Neoplasmsboth · compare here

Hoffmann-La Roche in Endometrial Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Endometrial Neoplasms in search

Qilu Pharmaceutical in Endometrial Neoplasms: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Endometrial Neoplasms in search

Esophageal Squamous Cell Carcinomaboth · compare here

Hoffmann-La Roche in Esophageal Squamous Cell Carcinoma: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Esophageal Squamous Cell Carcinoma in search

Qilu Pharmaceutical in Esophageal Squamous Cell Carcinoma: 1 program

  1. QLC5508phase 3

Their studies: Qilu Pharmaceutical’s studies of Esophageal Squamous Cell Carcinoma in search

Glomerulonephritis, IGAboth · compare here

Hoffmann-La Roche in Glomerulonephritis, IGA: 1 program

  1. sefaxersenphase 3

Their studies: Hoffmann-La Roche’s studies of Glomerulonephritis, IGA in search

Qilu Pharmaceutical in Glomerulonephritis, IGA: 1 program

  1. QLS7305phase 2

Their studies: Qilu Pharmaceutical’s studies of Glomerulonephritis, IGA in search

Hypertensionboth · compare here

Hoffmann-La Roche in Hypertension: 1 program

  1. zilebesiranphase 3

Their studies: Hoffmann-La Roche’s studies of Hypertension in search

Qilu Pharmaceutical in Hypertension: 1 program

  1. QLS1410phase 2

Their studies: Qilu Pharmaceutical’s studies of Hypertension in search

Keratoconjunctivitis Siccaboth · compare here

Hoffmann-La Roche in Keratoconjunctivitis Sicca: 1 program

  1. lifitegrastapproved, new study

Their studies: Hoffmann-La Roche’s studies of Keratoconjunctivitis Sicca in search

Qilu Pharmaceutical in Keratoconjunctivitis Sicca: 1 program

  1. lifitegrastphase 1

Their studies: Qilu Pharmaceutical’s studies of Keratoconjunctivitis Sicca in search

Lymphoma, Large B-Cell, Diffuseboth · compare here

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Qilu Pharmaceutical in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. selinexorphase 3

Their studies: Qilu Pharmaceutical’s studies of Lymphoma, Large B-Cell, Diffuse in search

Nasal Polypsboth · compare here

Hoffmann-La Roche in Nasal Polyps: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of Nasal Polyps in search

Qilu Pharmaceutical in Nasal Polyps: 1 program

  1. tezepelumabphase 3

Their studies: Qilu Pharmaceutical’s studies of Nasal Polyps in search

Ovarian Neoplasmsboth · compare here

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Qilu Pharmaceutical in Ovarian Neoplasms: 1 program

  1. Platinum Compoundsphase 2

Their studies: Qilu Pharmaceutical’s studies of Ovarian Neoplasms in search

Pancreatic Neoplasmsboth · compare here

Hoffmann-La Roche in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Pancreatic Neoplasms in search

Schizophreniaboth · compare here

Hoffmann-La Roche in Schizophrenia: 1 program

  1. ralmitarontphase 2

Their studies: Hoffmann-La Roche’s studies of Schizophrenia in search

Qilu Pharmaceutical in Schizophrenia: 1 program

  1. 3-6mg QLM1016phase 3

Their studies: Qilu Pharmaceutical’s studies of Schizophrenia in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Hoffmann-La Roche 39 of 80 · Qilu Pharmaceutical 18 of 72 programs (37 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25).